Pharmacokinetic properties of new oral anticoagulants and their clinical
application cases

doi:10.3760/cma.j.issn.1007-1245.2022.19.032

Abstract

Abstract: In recent years, new oral anticoagulant drugs have become the main anticoagulation regimens in the treatment of thromboembolic diseases. Compared with vitamin K antagonists, they have higher anticoagulant effects, so that more new options for anticoagulation and antithrombotic methods have been obtained. At present, there are many types of new oral anticoagulant drugs with a short half-life, different drug effects, and different therapeutic effects. Therefore, this paper analyzes the pharmacokinetics of ximegatran (withdrawn from the market), dabigatran etexilate, rivaroxaban, and apixaban and clarifies the clinical application status of different anticoagulant drugs, so as to ensure the rationality of the application of new oral anticoagulant drugs in clinical practice.

Key words: New oral anticoagulants, Pharmacology, Vitamin K antagonists, Thromboembolic disease

摘要： 近年来，新型口服抗凝药物成为治疗血栓栓塞性疾病的主要抗凝方案，较维生素K拮抗剂，其具有较高的抗凝效果，使抗凝抗栓方法获得较多新选择。目前，新型口服抗凝药物种类较多、半衰期短，不同药物之间的药物作用不同，治疗效果也不同。因此，本文对希美加群（已撤市）、达比加群酯、利伐沙班、阿哌沙班的药动力学进行分析，并对不同抗凝药物临床应用现状进行阐明，以此在最大程度上保障新型口服抗凝药物在临床实践中的应用合理性。

关键词: 新型口服抗凝药物, 药理学, 维生素K拮抗剂, 血栓栓塞性疾病

Yao Hongyan. Pharmacokinetic properties of new oral anticoagulants and their clinical application cases [J]. International Medicine and Health Guidance News, 2022, 28(19): 2809-2812.

姚鸿雁. 新型口服抗凝药物的药动学特性及其临床应用案例[J]. 国际医药卫生导报, 2022, 28(19): 2809-2812.

References

[1] Milling TJ, Ziebell CM. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery[J]. Trends Cardiovasc Med, 2020,30(2):86-90. DOI: 10.1016/j.tcm.2019.03.004.
[2] 丁征,潘文斐,郑英丽.新型口服抗凝药物及拮抗剂的发展现状与上市研究[J].药品评价,2019,16(2):9-12,38.
[3] 王晨曦,吴丹,杨萍萍,等.NOAC与VKA口服抗凝药在预防和治疗活动性癌症患者血栓性疾病中有效性和安全性的荟萃分析[J].中华心血管病杂志,2020,48(8):689-696.DOI:10.3760/cma.j.cn112148-20200630-00529.
[4] 刘岳,任怡荣,朱火兰,等.新型口服抗凝药物在非瓣膜性心房颤动患者中的应用及挑战[J].中国全科医学,2020,23(23):2872-2873,2894.DOI:10.12114/j.issn.1007- 9572.2020.00.364.
[5] 尼加提•尼亚孜,艾力菲热•帕尔哈提,刘帅,等.口服抗凝药物治疗的心房颤动患者出血与血小板计数之间的相关性分析[J].新疆医科大学学报,2020,43(2):140-144,148.DOI:10.3969/j.issn.1009-5551.2020.02.004.
[6] 魏倩,梁岩.新型口服抗凝药物与维生素K拮抗剂相关的脑出血风险对比[J].心血管病学进展,2020,41(5):441-443,451.DOI:10.16806/j.cnki.issn.1004-3934.2020.05.001.
[7] 程芳,郝倩,司海娇,等.高龄老年非瓣膜性房颤患者应用新型口服抗凝药物的情况分析[J].空军医学杂志,2020,36(4):355-357.DOI:10.3969/j.issn.2095-3402.2020.04.024.
[8] 余瑷砾,熊雪.达比加群酯对房颤伴心力衰竭患者的临床疗效[J].心血管康复医学杂志,2020,29(3):345-349.DOI:10.3969/j.issn.1008-0074.2020.03.20.
[9] 田晓江,王晓莉,王柯静,等.基于美国FDA不良事件报告数据库的达比加群酯相关出血事件信号检测与分析[J].药物不良反应杂志,2020,22(7):398-403.DOI:10.3760/cma.j.cn114015-20190726-00612.
[10] Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation[J]. N Engl J Med, 2020,383(18):1735-1745. DOI: 10.1056/NEJMoa2012883.
[11] 王昌会,林先和,陈大年,等.利伐沙班在房颤射频消融围术期临床应用[J].安徽医科大学学报,2020,55(5):763-767.DOI:10.19405/j.cnki.issn1000-1492.2020.05.021.
[12] 孙沙沙,曹剑,刘宏斌,等.利伐沙班治疗老年血栓性疾病患者的疗效和安全性[J].中华老年医学杂志,2020,39(1):43-46.DOI:10.3760/cma.j.issn.0254-9026.2020.01.008.
[13] 梁岩,龚泽彬,娄可佳,等.利伐沙班与阿司匹林联用在中国稳定性心血管疾病患者中的有效性及安全性评价:COMPASS研究中国亚组分析[J].中华心血管病杂志,2021,49(9):873-879.DOI:10.3760/cma.j.cn112148-20210319- 00247.
[14] 陈峰,高昶.凝血因子Ⅹa抑制剂阿哌沙班的专利布局及专利技术特点和启示[J].国际药学研究杂志,2020,47(9):709-715,721.DOI:10.13220/j.cnki.jipr.2020.09.005.
[15] 李鸿飞,兰光明.成都西部地区老年非瓣膜病房颤患者抗凝的治疗现状[J].昆明医科大学学报,2019,40(4):121-125.DOI:10.3969/j.issn.1003-4706.2019.04.025.
[16] 钟云恒,李亮,符峰梁.利伐沙班与华法林治疗冠心病合并非瓣膜性房颤患者的效果及安全性[J].临床和实验医学杂志,2022,21(10):1021-1025. DOI:10.3969/j.issn.1671- 4695.2022.10.004.
[17] Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace, 2015,17(10):1467-507. DOI: 10.1093/europace/euv309.
[18] 邢宇,栗印军.利伐沙班、达比加群酯和华法林用于高龄非瓣膜性房颤病人抗凝治疗的有效性和安全性对比研究[J].中西医结合心脑血管病杂志,2019,17(3):411-413.DOI:10.12102/j.issn.1672-1349.2019.03.025.
[19] 陈艳梅,武云涛,刘立新.利伐沙班与达比加群酯在高龄非瓣膜病性房颤患者长期抗凝治疗的疗效及安全性[J].中国循证心血管医学杂志,2020,12(9):1059-1061,1066.DOI:10.3969/j.issn.1674-4055.2020.09.09.
[20] 赵紫楠,孙雪林,胡欣.直接口服抗凝药预防骨科大手术后静脉血栓栓塞症疗效与安全性的系统评价[J].中国循证医学杂志,2019,19(10):1217-1225.DOI:10.7507/1672-2531.201905056.
[21] McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial[J]. J Thromb Haemost, 2020,18(2):411-421. DOI: 10.1111/jth.14662.
[22] Marshall A, Levine M, Hill C, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)[J]. J Thromb Haemost, 2020,18(4):905-915. DOI: 10.1111/jth.14752.
[23] 刘群峰.利伐沙班与低分子肝素治疗老年人恶性肿瘤并发静脉血栓栓塞症的效果比较[J].中国基层医药,2020,27(14):1675-1678.DOI:10.3760/cma.j.issn.1008-6706. 2020.14.003.
[24] 周元,许邦龙,高峰.心房颤动合并冠心病冠状动脉介入治疗术后达比加群酯抗凝治疗的有效性及安全性研究[J].安徽医药,2019,23(4):657-661.DOI:10.3969/j.issn.1009- 6469. 2019.04.006.
[25] Khan SU, Arshad A, Riaz IB, et al. Meta-analysis of the safety and efficacy of the oral anticoagulant agents (Apixaban, Rivaroxaban, Dabigatran) in patients with acute coronary syndrome[J]. Am J Cardiol, 2018,121(3):301-307. DOI: 10.1016/j.amjcard.2017.10.035.
[26] Sycheva NA, Koroleva LY, Nosov VP, et al. Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study[J]. Kardiologiia, 2020,60(7):53-63. DOI: 10.18087/cardio.2020.7.n954.
[27] 冯瑞江,熊爱珍,梁佳,等.心房颤动伴肝功能不全患者口服抗凝药物的合理使用[J].临床心血管病杂志,2019,35(2):187-192.DOI:10.13201/j.issn.1001-1439.2019.02.021.
[28] 朱淑容,李幼菁,李瑞,等.某区域医院新型口服抗凝血药(dabigatran)之药物使用评估[J].安泰医护杂志,2018,24(1):55-65.
[29] 陈玮婷,杨莉,张亚清.高龄肾功能异常房颤患者应用达比加群酯病例分享[J].临床药物治疗杂志,2019,17(3):43-46.DOI:10.3969/j.issn.1672-3384.2019.03.011.
[30] Bratsos S. Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects[J]. Cureus, 2019,11(8):e5484. DOI: 10.7759/cureus.5484.

Pharmacokinetic properties of new oral anticoagulants and their clinical application cases

新型口服抗凝药物的药动学特性及其临床应用案例

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics